Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey Zonder, M.D.
Barbara Ann Karmanos Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Karmanos Cancer Institute
Detroit, Michigan, United States
Abhinav Deol, M.D.Andrew Kin, M.D.Craig Cole, M.D.Dipenkumar Modi, M.D.Indryas L Woldie, M.D.Jay Yang, M.D.Jeffrey Zonder, M.D.Joesph Uberti, M.D. PhDLois Ayash, M.D.Melissa Runge Morris, M.D.Suresh Balasubramanian, M.D.Vijendra Singh, M.D.Recruiting - Kci at Mclaren Greater Lansing
Lansing, Michigan, United States
Craig Cole, M.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Dec 2023
- Primary completion
- 31 Dec 2027
- Completion
- 31 Dec 2028
- Last update posted
- 26 Jun 2026
- Registered enrollment
- 60
- Registry id
- NCT06107738
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.